Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. European Medicines Agency

Evaluate

November 21, 2017

Who could lose as European drug regulation moves to Amsterdam?

November 13, 2017

Alnylam: The $12bn company with the $2bn war chest

Article image
Vantage logo
October 25, 2017

European approvals face delay from agency move

How the EMA's move out of London could impact European drug approvals.

Vantage logo
October 02, 2017

Ablynx sees payoff from Hercules labours

Vantage logo
August 07, 2017

Interview – Santhera readies muscular dystrophy push

Vantage logo
April 28, 2017

Snippets roundup: Sanofi diabetes disappointment, and Amgen pullback signals CGRP caution

Vantage logo
April 19, 2017

Ultragenyx bounces back, but painful questions remain

Vantage logo
January 13, 2017

Upcoming events – Life beyond sola and Ampyra for Lilly and Acorda

Vantage logo
January 11, 2017

JP Morgan day two roundup – all talk, very little action

Vantage logo
December 23, 2016

Snippet roundup: Biogen's chief exec choice underwhelms as a big 2016 decision is delayed to 2017

Vantage logo
November 23, 2016

Novo and Sanofi cut thinner slice of the diabetes pie

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up